1. Academic Validation
  2. 6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents

6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents

  • J Med Chem. 2010 Jan 14;53(1):460-70. doi: 10.1021/jm901428k.
Petr Naus 1 Radek Pohl Ivan Votruba Petr Dzubák Marián Hajdúch Ria Ameral Gabriel Birkus Ting Wang Adrian S Ray Richard Mackman Tomas Cihlar Michal Hocek
Affiliations

Affiliation

  • 1 Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic.
Abstract

A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or hetaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with alkyl- or (het)arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with (het)arylboronic acids. Significant cytostatic effect was detected with a substantial proportion of the prepared compounds. The most potent were 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple Cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabine. Intracellular phosphorylation to mono- and triphosphates and the inhibition of total RNA synthesis was demonstrated in preliminary study of metabolism and mechanism of action studies.

Figures